Pfizer: FDA approves expanded use for anti-tumor drug.
(CercleFinance.com) - On Friday the United States Food and Drug Administration approved the expanded use of Pfizer's Sutent for the treatment of patients who are at high risk of their renal cell carcinoma returning after surgery.
The US FDA has approved a new indication expanding the use of Sutent to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.
The approval was based on results from a trial which demonstrated a significant reduction in the risk of a disease-free survival event, Pfizer said.
The median disease-free survival was 6.8 years in the Sutent arm compared with 5.6 years for placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The US FDA has approved a new indication expanding the use of Sutent to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.
The approval was based on results from a trial which demonstrated a significant reduction in the risk of a disease-free survival event, Pfizer said.
The median disease-free survival was 6.8 years in the Sutent arm compared with 5.6 years for placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.